Heparin is usually obtained from mammalian organs, such as beef lung, beef mucosa, porcine mucosa, and sheep intestinal mucosa. Because of the increased use of heparin in the production of low-molecular-weight heparin (LMWH), there is a growing shortage of the raw material needed to produce LMWHs. A previous report described the structural features of a novel LMWH from the shrimp (Penaeus brasiliensis). In order to compare anticoagulant and antiprotease effects of this heparin, global anticoagulant tests, such as the prothrombin time, activated partial thromboplastin time, thrombin time, and Heptest&reg;, were used. Amidolytic anti-Xa and anti-IIa activities were also measured. The relative suscep-
tibility of this heparin to flavobacterial heparinase was also evaluated. The United States Pharmacopeia (USP) potency of shrimp heparin (SH) was found to be 28 U/mg. SH However, the anti-Xa activities were only partially neutralized.
Protamine sulfate was only partially effective in neutralizing the anticoagulant and antithrombin effects of SH. SH also produced marked prolongation of activated clotting time, which was neutralized by heparinase but not by protamine sulfate. These results suggest that SH is a strong anticoagulant with comparable properties to mammalian heparins and can be used in the development of clinically useful antithromboticanticoagulant drugs. Key Words: Shrimp heparin&mdash; Pinaeus brasiliensis&mdash; Heparinlike compound&mdash;Invertebrate heparin. Unfractionated heparins (UFH) is one of the oldest anticoagulant drugs still used in widespread ~tinic~l conditions. Although bleeding complication« and heparininduced thrombocytopenia represent major side effects of this drug, UFH has remained the agent of choice for prophylaxis and management of thrombotic disorders and for anticoagulation in surgical interventions (1) . In the past decade, p~ ac~htical industries allocated sizresources to finding an alternative for heparin because of its side effects. Low-molecular-weight heparins, (LMWHs) are a group of heparin-derived anticoagulantantithrombotic agents that began their development dur-ing the last quarter of this century. UFH is usually obtained from mammalian organs, such as beef lung, beef intestinal mucosa, porcine intestinal mucosa, and sheep intestinal mucosa (2) . UFH is also used for production of LMWHs, which exhibit a number of improved features ' compared with UFH. LMWHs now available commercially are manufactured by chemical or enzymatic depolymerization of porcine mucosal heparin preparations. Physical methods such as irradiation and ultrasonication have also been used to prepare these agents (3, 4) . Because of the increased use of UFH in the production of ' LMWHs, there is a growing shortage of raw material needed to produce LMWH. Substitutes for UFH and LMWHs have long been sought. Some natural, synthetic, and biologic products were developed instead of UFH and L1V~'~Hs (5) . ' Previous studies have shown that heparinlike compounds with high anticoagulant activity are present in some invertebrates, such as mollusks (Cyprinia. a'.~tt~t~dic~rz, Mactrus pussitla, Anomalocardia brasiliatia, Donnax~r ici~cr~, and Tivela ata~actr~ic~~.s) (fi-~-~) and clams (Mer-;~rac~t-~~t mercenaria) (9) . The heparinlike compounds, which are obtained from some invertebrates, are similar to those obtained from mammalian origins and exhibit similar structure and anticoagulant activities. Enzymatic and nitrous acid degradation, as well as 1 3C and 'H nuclear magnetic resonance spectroscopy, have shown that mollusk heparins were similar to those of mammalian origin (10, 11) . A previous report has described the structural features of a novel heparinlike compound from shrimp (f'c~fiuc~cc.l~t~c t:s~lic~tz~i.s) (12) . The structural features of the sulfated glycosaminoglycan isolated from the viscera of the shrimp are similar to those features of mammalian hepains. This heparinlike compound has a low molecular weight enriched with nonsulfated uronic acid residues and exhibits a potent antithrombotic activity.
The aim of this study is to determine the anticoagulant-antithrombotic profiles of the shrimp heparin (SH) and evaluate the relative susceptibility of this h~pariz~li~C~F IG. 1. Effects of shrimp heparin on various clc~t based assays-prothrombin time, activated ~~t~i~l thromboplastin time, Heptest, and thrombin time (5U).
compound to flavobacterial heparinase I and protamine sulfate (PS). The anticoagulant and antithrombotic profile of SH is also compared with the effects of UFH and enoxaparin, an approved LMWH.
MATERIALS AND METHODS 1 ) Shrimp heparin was obtained from Dr. Carl P. Dietrich's laboratory (Sao Paulo, Brasil). This compound was produced from shrimp heads containing viscera. The extraction, p~ril~~;atir~n § and enzymatic degradation by heparinases of SH were also performed (12) . The molecular weight of SH as determined by polyacrylamide gel electrophoresis (stained with toluidine blue) is approximately 10 kd. 2) Heparinase I (EC 4.2.2.7; IBEX Technologies Inc., Montreal, Canada), and PS (Laboratory Choay, Paris, France) were utilized for the neutralization study of SH. Heparinase I was added at a concentration of (~, 1 CTlml to each concentration of drug. PS, 25 ~g/m!, was used for the neutralization study. SH was used in a concentration range of 0 to 25 ~~l~l. 3) Enoxaparin (Aventis Pharmaceuticals, Collegeville, PA) and UFH (Laboratory Choay, Paris, France) were used for the comparative study with SH. The concentration range of these drugs was 0 to 25 '~glm~: 4) Activated clotting time (ACT): Hemochron instrument and celite-ACT tubes were obtained from International Technidyne Corporation (Edison, NJ). Blood was drawn up to 2 ml in each set of syringes to obtain a final concentration of 12.5 Rt,/i-nl, 25 p,~/ml, 50 ~Lg/m!. and saline control, ACTs were performed by the standard procedure and results were recorded. 5 
RESULTS
n Anticoagulant profile of SH: SH produced a concentration-dependent prolongation of all of the clotting tests, such as APTT, Heptest, and 5U TT, except PT (Fig. 1 )* SH produced a stronger effect on APTT and TT (5U) than the Heptest. The United States Pharmacopeia (USP) potency of SH was found to be 28 U/mg.
2) Antiprotease profile of ;~H: SH exhibited marked inhibition of FXa and Flla (Fig. 2 ). Anti-Xa activity is stronger than the anti-Ila activity. This property of SH is similar to the feature of LMWHs.
3) Effect of SH on the ACT and its neutralization by heparinase ! I ~n~ P&dquo;~:' In the ACT assay, SH exhibited a concentration-dependent prolongation of clotting time (Fig. 3 ). Whereas heparinase treatment at a 0.1 I U/ml dosage resulted in a dramatic decrease of the anticoagulant effects of SH, PS at 25 ~g/m! was not neutralized in the ACT assay ( Fig. 4 ) (One way of variance analysis P = 0.004, Newman-Keuls SH+PS vs. SH P > 0.05: SH + Heparinase vs. SH P -~.~ l ). 4) Effect of SH as measured by TEG method and its neutralization by heparinase: TEG analysis showed that SH produced a strong anticoagulant effect, which is completely neutralized by heparinase I but not by PS (Fi~. 5, Fig. 6 , and Table U . 5) Comparative studies on the neutralization of the SH by PS and heparinase as measured by various tests:
The effects of the neutralization studies can be measured by different clotor amidolytic-based assays. Heparinase treatment resulted in a marked decrease of the anticoagulant effect and neutralized the APTT ( P = ~.t) I ; Fig. 7 ), Heptest (P = 0.01; Fig. 8 ), TT (t' = f).~ 1; Fig. 9 ) and anti-Ila activity (P = 0.009; Fig. l t~) . However, anti-Xa activity was only partially neutralized (P > 0.05; Fig. 11 ). PS was only partially effective in neutralizing the anticoagulant and antithrombin effects of SH (APTT, P > 0.05; Heptest, P > 0.05; TT, P > 0.05; anti-Xa, P > 0.05; anti-Ha, P > 0.05). Figures 15 and 16 show the results of anti-Xa and antilla activities.
6) Comparison of

DISCUSSION
Hepariniike compounds, which are present in some invertebrates, result in high anticoagulant activity, and their structural properties are similar to mammalian heparins. A few differences, however, are observed (11-14~; Some compounds have a higher degree of binding with antithrombin III (ATIII), higher affinity to heparin, cofactor II (HCII), higher molecular weight, and higher anticoagulant activity (10, 13) . A heparinlike compound was isolated from the viscera of the shrimp, P. brasilien-;sa.~, by Dietfich et al (12) . This compound has a tighter molecular weight than mammalian UFH, which is obtained from the porcine mucosa. The structural differences between the shrimp UFH and mammalian UFH reside mainly in the relative abundance of the different disaccharide units present in the heparins ('~ ~~. These differences have also been observed regarding the other invertebrate heparins.
The anticoagulant activity of SH is mainly dependent on the activation of serine proteases such as ATIII and HCII (12) . In the clot-based assays, SH exhibits a strong effect on the prolongation of clotting time. The effects of SH on APTT and TT (5U) are better than on Heptest. The anticoagulants potency of UFH and LMWHs are usually measured in tennis of a USP Unit/mg. The USP potency of SH was found to be 28 U/mg, which is variable as a result of different experiments. SH also produced marked inhibition of FXa and FIIa in amidolytic assays. The anti-Xa and anti-Ila activities of this compound depend on the AT III-and HC II--m~diated ' thrombin generation inhibition. ACT and TEG analyses were also performed to determine the anticoagulant activity of SH. These assays showed that SH prolonged the clotting time in a concentration-dependent manner.
PS is a traditional agent used to reverse the anticoagulant effect of UFH. However, PS does not completely reverse the effects of L:~I1~I-I:~. Heparinase also partially neutralized the effects of UFH, as well as LMWHs and some heparinomimetics (15) . Heparinase is an r:lin ~i~~s~su isolated from ~l~x~.e.rl~c~c~t~a~ictraa hepllrirwm and cleaves heparin at atta-gtycosidic linkages in its major repeating units. Preliminary studies suggest that heparinase may be equally as effective as protamine tor reversing heparin, and it does not cause substantial hemodynamic changes (16) . Heparinase neutratizes heparin by enzymatically cleaving the long s~c:ch~ridic chains of heparin into disaccharide (50%), tetrasacchandes (25%), hexasaccharides (15%), and larger saccharide chains (10%). This mixture contains 10 to 20% caf the anti-factor Xa activity of the original heparin dose; the anti-Ua activity is largely removed (17) . Heparinase treatment resulted in a dramatic decrease of the anticoagulant effects on clot-based assays such as APTT, TT, and Heptest and neutralized the anti-IIa actions by determining an amidolytic assay. However, the anti-Xa activities were only partially neutralized. Protamine sulfate was only partially effective in neutralizing the anticoagulant ' and antithrombin effects of SH.
In the comparative study, SH has a stronger anticoagulant effect than enoxaparin but a weaker effect than UFH. Based on anti-Xa and anti-Ha activity assays, SH is the weakest among these compounds. This difference probably depends on the affinity of these agents to the sefine protease. SUMMARY 1) The head and viscera of shrimp (P. l~rca~ilic~ras~s) consist of a heparinlike compound. 2) The structural and anticoagulant profile of this hepafinlike compound is similar to mammalian heparins. 
7)
When compared to mammalian heparin, the anticoagulant profile of SH is similar to LMWHS. Based on clotting tests, the ranked order is UFH > SH > enoxaparin. However, based on anti-Xa and anti-IIa activities, the ranked order is UFH > enoxaparin > SH.
CLINICAL IMPLICATIONS
Unfractionated heparin is utilized in the production of LMWHS. It has been shown that the some of the pharmacologic features of LMWHs are superior to UFH. Because of the increased use of UFH in the production of LMWH, there is a shortage of the raw material to produce LMWHS. For reasons, the new agents have been sought instead of UFH. Previous studies have showed that heparinlike compounds are present in some invertebrates such as mollusks and clams. SH is a hepafinlike compound obtained from the head and the viscera of shrimp. SH is a strong anticoagulant agent with comparable properties to mammalian heparins. The structure and anticoagulant-antithrombotic profile of the heparinlike compound is similar to LMWHs. In the future, SH can be used in the development of clinically useful antithrombotic and anticoagulant drugs. Shrimp heparin is found to exhibit similar anticoagulant and antiprotease profiles in comparison to heparins and warrants in vivo evaluation in the animal models of thrombosis and bleeding disorders. Based on these studies and toxicology screening, SH can be developed as an anticoagulant drug for clinical applications.
